Preclinical in vivo evaluation of sFLT secretion gene therapy for retinal and choroidal neovascularisation

该项目的目的是开发糖尿病相关视网膜新生血管的长期治疗方法，减少糖尿病性黄斑水肿的发生，并在视力丧失之前为老年性黄斑变性相关脉络膜新生血管提供高效的治疗方法。该技术对目前的激光光凝、玻璃体切割和光动力治疗提供了显著的改进或补充治疗，可能是疾病管理的重大进步。所提出的策略利用重组病毒介导的基因传递，基本上在疾病的位置特异性地产生治疗剂。这些解决分泌基因治疗（SGT）可行性的研究将很容易适用于我们的基因发现计划拨款（JDRF-NHMRC 219166），旨在确定新的抗血管生成基因。

The aim of this project is to develop a long-term treatment for diabetes-related retinal neovascularisation, reduce the occurrence of diabetic macular oedema and provide a highly effective treatment for age-related macular degeneration related choroidal neovascularisation before vision loss. The proposed technique would potentially be a major advance in disease management by providing a significantly improved or complementary treatment to the current therapies of laser photocoagulation, vitrectomy and photodynamic therapy. The proposed strategy utilizes recombinant virus-mediated gene delivery which basically produces the therapeutic agent specifically at the location of the disease. These studies addressing the feasibility of secretion gene therapy (SGT) will be readily applicable to our Gene Discovery Program Grant (JDRF-NHMRC 219166) that is set out to identify new anti-angiogenic genes.